Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

GI Dynamics’ EndoBarrier

This article was originally published in The Gray Sheet

  • News

Executive Summary

Firm gains CE mark approval of its EndoBarrier gastrointestinal liner device to treat obesity and type 2 diabetes. A sham-controlled pilot trial presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York in September showed that EndoBarrier reduces average blood glucose levels in patients with type 2 diabetes (1"The Gray Sheet" Oct. 6, 2008, p. 22). Another recently published study shows EndoBarrier imitates the treatment effect of Roux-en-Y bypass surgery, including weight loss and improved metabolic function in rats with diet-induced obesity (2"The Gray Sheet" Nov. 24, 2008, p. 16). The company is planning to conduct larger, long-term trials in 2009

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT026977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By